Publication Year

Mihalchik AL, Roberts A, LaCombe J, Lloyd M, Doepker C, Eapen A. 2026. Evaluation of the safety and potential genotoxicity of a high-purity mogroside ingredient containing siamenoside I produced from a modified strain of Yarrowia lipolytica. Toxicol Rep 17(Dec):102297; doi: 10.1016/j.toxrep.2026.102297. PMID: 42388455.

Frankenfeld CL, Movva N, Hooda N, Gauthier J, Reichert H, Doepker C. 2026. Analysis of National Health and Nutrition Survey (NHANES): Nutrient, food, and beverage intake of GLP-1-RA users with type 2 diabetes, 2007-2020. J Nutr 101685; doi: 10.1016/j.tjnut.2026.101685. Online ahead of print June 22. PMID: 42331063.

Zemrani B, Hays NP, Movva N, Reichert H, Pados B,  Saavedra JM. Parental reporting of gastrointestinal symptoms in healthy breastfed infants varies across geographies and age groups: A systematic review and meta-analysis. E-Poster EPV739/ID 3665, ESPGHAN 2026: 58^th Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, Lille, France, June 24-27, 2026.

Buerger AN, Thompson CM, Heintz MM, Maberti S, Palermo CM, Haws LC. 2026. Application of quantitative and qualitative uncertainty assessment risk management decision-making: A case study with diisononyl phthalate. Food Chem Toxicol 214(Aug):116110; doi: 10.1016/j.fct.2026116110. PMID: 42035978.

Perreault L, Rasouli N, Sanogo F, Movva N, Bylsma L, Suh M, Reichert H, Donsmark M, Girguis M, Frankenfeld C. A meta-analysis of persistence and adherence to glucagon-like peptide 1-based treatments among patients with type 2 diabetes in the United States. Abstract/Poster 1691-P, American Diabetes Association 2026 Scientific Sessions, New Orleans, LA, June 7, 2026.

Torres C, Kramer A, Racz L, Vivanco S, Panko J. Anticipating number of days that exceed OSHA proposed heat triggers. Abstract 1501, Poster Session 3, AIHA Connect 2026, New Orleans, LA, June 3, 2026.

Kramer M, Torres CV. Feasibility assessment of EPA’s OEVs/ECELs. Research Roundup Presentation C1b, AIHA Connect 2026, New Orleans, LA, June 1, 2026.

Haws L (Moderator), Maxwell G (Speaker), Kleinstreuer N, Lowit A, Harrill J (Panelists). Next generation risk assessment (NGRA): Emerging best practice & opportunities for regulatory use. Society of Toxicology Risk Assessment Specialty Section (RASS) Risk Assessment Syllabus Webinar, June 17, 2026.

Fender CL, Morshead M, Schindler J, Williamson M, Brown K, Cohen C, Feldman L, et al. 2026. Addressing community concerns about unregulated organic contaminants in surface water: Integrating suspect and non-targeted chemical analyses with Zebrafish toxicity testing and computational hazard comparisons. Environ Pollut 399(15 June):128103; doi: 10.1016/j.envpol.2026.128103. PMID: 41997357.

Kirman CR, Lipscomb JC, Rogers J, Schoeny RS, Seed JG, Sonawane BR, Hays SM. 2026. Evaluation of the modes of action for key noncancer effects of 1,3-Butadiene: Input from an independent expert panel to support derivation of data-derived extrapolation factors. Crit Rev Toxicol; doi: 10.1080/10408444.2026.2661191. Online ahead of print June 9. PMID: 42261678.

Bond G, Becker RA, Rish W, Ryman JP, Verwiel AH. 2026. Cumulative impact assessment within vulnerable communities: Challenges, opportunities and path forward. J Toxicol Regul Pol 2(1):1-19; doi: 10.69982/JTRP-25-0012.

Kennedy SB, Heintz MM, Brown L, Fender CL, Hecker M, Hughes SA, Naile J, DeLeo P. Defining the domain of applicability: A case study to increase confidence in toxicogenomic tools for ecological risk assessment. Poster 1.03.P-Tu032, SETAC Europe 36^th Annual Meeting, Maastricht, The Netherlands, May 19, 2026.

Wigh A, Campos B, de Croze N, Roush K, Suzuki T, Brown L, Kennedy SB, Hecker M, et al. Chronic fish toxicity case studies toward a best practice guidance document. Poster 1.09P-Mo042, SETAC Europe 36^th Annual Meeting, Maastricht, The Netherlands, May 18, 2026.

Rethlefsen ML, Brigham TJ, Price C, Reynolds JM. From brie-f comments to lasting revisions: Librarian peer review in action. Research paper presentation, Annual Meeting of the Medical Library Association, Milwaukee, WI, May 2026. Awarded 2^nd Place Paper by research awards judging team.

Flume PA, Nordyke RJ, Han D, Jha A, Nicholson G, Peipert JD. 2026. Patient-reported outcome measures developed for non-cystic fibrosis bronchiectasis may be applied to cystic fibrosis bronchiectasis. Health Qual Life Outcomes; doi: 10.1186/s12955-026-02546-4. Online ahead of print May 13. PMID: 42129785.

Nordyke RJ. Panel Moderator: Can new approaches to estimating dynamic efficiency help to maintain both access and innovation in pharmaceutical markets? ISPOR 2026, Philadelphia, PA, May 19, 2026.

Nordyke RJ, Cyr P, Jensen I. Gene therapy development programs are both growing and evolving in the face of commercial headwinds. Poster Session 3/No. HPR71, ISPOR 2026, Philadelphia, PA, May 19, 2026.

Nordyke RJ, Jensen I, Hooda N, Miller B. Rising levels of innovation in expedited designations among FDA-approved drugs: 2012-2024. Poster Session 2/No. HPR63, ISPOR 2026, Philadelphia, PA, May 18, 2026.

Fitch S, Lozy F, Mitchell C, Patlewicz G, Wood A. Use of new approach methodologies in the safety assessment of dietary supplements—Parts one and two. Webinar series, Council for Responsible Nutrition (CRN), Washington, DC, May 2026.

Thompson CM, Heintz MM, Rogers SI, Vincent MJ, Haws LC. 2026. Integration of mechanistic and repeat dose toxicity data in the derivation of an oral reference dose for HFPO-DA. Toxicol Sci 209(5):kfag045; doi: 10.1093/toxsci/kfag045. PMID: 41968070.